Funder
National Natural Science Foundation of China
Reference46 articles.
1. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019;Collaborators;Lancet Gastroenterol Hepatol,2022
2. Countdown to 2030: eliminating hepatitis B disease, China;Liu;Bull. World Health Organ.,2019
3. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients;Su;Liver Int.,2016
4. Outcomes of long-term treatment of chronic HBV infection with entecavir or other Agents from a randomized trial in 24 countries;Hou;Clin. Gastroenterol. Hepatol.,2020
5. Antiviral therapy reduces risk of cirrhosis in noncirrhotic HBV patients among 4 urban safety-net health systems;Wong;Am. J. Gastroenterol.,2021